drug_type
RELEVANT_DRUG
intervention_type
Cellular Therapy
drug_description
Autologous T cells engineered to express a chimeric antigen receptor targeting BCMA (TNFRSF17) on malignant plasma cells, mediating cytotoxicity via perforin/granzyme and cytokine release.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells are genetically engineered to express a chimeric antigen receptor targeting BCMA (TNFRSF17) on malignant plasma cells. Antigen engagement activates the T cells to proliferate and kill BCMA-expressing cells via perforin/granzyme-mediated cytotoxicity and cytokine release.
drug_name
BCMA-directed CAR T cells
nct_id_drug_ref
NCT05860036